Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$56.17 USD

56.17
809,406

-0.16 (-0.28%)

Updated Aug 30, 2024 01:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche to Evaluate Actemra for Severe COVID-19 Pneumonia

by Zacks Equity Research

Roche (RHHBY) works with the FDA to evaluate the safety and efficacy of rheumatoid arthritis drug, Actemra, in severe COVID-19.

Ekta Bagri headshot

Drugs or Vaccines: Which Will Be More Crucial Against Coronavirus?

by Ekta Bagri

Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.

The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA

by Zacks Equity Research

The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA

Kinjel Shah headshot

Pfizer, Regeneron Give Update on Coronavirus Drug Development

by Kinjel Shah

Pfizer (PFE) to jointly develop BioNTech's potential coronavirus vaccine. Regeneron (REGN) could start clinical studies of a COVID-19 therapy by this summer.

Mark Vickery headshot

Top Stock Reports for UnitedHealth, Sanofi & United Parcel

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Sanofi (SNY) and United Parcel Service (UPS).

Madeleine Johnson headshot

These 10 Drug Companies are Testing a Coronavirus Vaccine

by Madeleine Johnson

As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Kinjel Shah headshot

Regeneron/Sanofi to Test Kevzara for Severe Coronavirus Infection

by Kinjel Shah

A U.S. based phase II/III study has been initiated to evaluate Regeneron (REGN)/Sanofi's (SNY) rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19.

Inovio (INO) Stock Up YTD on Coronavirus Vaccine Efforts

by Zacks Equity Research

Inovio (INO) is developing INO-4800, its DNA vaccine to enter clinical testing soon, against COVID-19. The company's vaccine portfolio holds potential amid competition.

J&J Signs Another Collaboration to Develop Coronavirus Vaccine

by Zacks Equity Research

J&J (JNJ) is actively pursuing its development plans related to coronavirus vaccine. The company is partnering with several public/private organizations to accelerate its vaccine development.

Inovio (INO) Posts Wider Q4 Loss, Gets COVID-19 Vaccine Grant

by Zacks Equity Research

Inovio's (INO) loss in the fourth quarter falls shy of estimates and revenues too miss the mark. The company is focused on developing INO-4800, its DNA vaccine, against COVID-19.

AMAG Sees High Feraheme Sales, To Sell Women Healthcare Drugs

by Zacks Equity Research

AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.

Kinjel Shah headshot

Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates

by Kinjel Shah

Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.

Lilly Expects No Drug Supply Shortages Due to Coronavirus

by Zacks Equity Research

Lilly (LLY) does not expect shortage in supply of its medicines as it does not source APIs of any of its marketed drugs from China.

5 Drug Makers to Gain From Coronavirus Outbreak

by Zacks Equity Research

Drug makers globally are working on developing therapies and vaccines for coronavirus. Here are five stocks that are currently in focus.

Sanofi's Sarclisa Gets FDA Nod for Third-Line Multiple Myeloma

by Zacks Equity Research

The FDA approves Sanofi's (SNY) Sarclisa (isatuximab) combo for the treatment of adult patients with relapsed refractory multiple myeloma in the third-line setting.

Kinjel Shah headshot

5 Biotechs That Escaped the Coronavirus Onslaught Last Week

by Kinjel Shah

Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.

Madeleine Johnson headshot

These 6 Drug Companies are Testing a Coronavirus Vaccine

by Madeleine Johnson

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Madeleine Johnson headshot

These 6 Drug Companies are Testing a Coronavirus Vaccine

by Madeleine Johnson

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit

by Kinjel Shah

FDA accepts Glaxo (GSK) and Novartis' (NVS) sBLA. FDA gives approval to Lilly's (LLY) Trulicity for cardiovascular indication.

Esperion (ESPR) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports encouraging fourth-quarter results. The company is set to launch its first drug next month.

BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus

by Zacks Equity Research

BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.

Sanofi Plans Spin-Off of API Unit Into a European Company

by Zacks Equity Research

Sanofi (SNY) plans to combine its API commercial activities with six of its European API production sites and spin-off the same into an independent European API company.

    BioMarin (BMRN) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Key orphan disease drugs, Vimizim and Kuvan, are likely to have driven BioMarin's (BMRN) fourth-quarter top line.

    Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates

    by Zacks Equity Research

    Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.

    Kinjel Shah headshot

    Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval

    by Kinjel Shah

    AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.